

SHREE GANESH BIO-TECH(INDIA)LIMITED

L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA
Kolkata WB 700020 IN

E Mail: shreeganeshbiotechindiaLtd@gmail.com

Date: 12th July, 2017

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange
of India Limited
Vibgyor Towers, 4th floor, Plot
No C 62, Opp. Trident Hotel
Bandra Kurla Complex, Bandra
(E),
Mumbai - 400098
Scrip Code: SHREEGANES

Scrip Code: 539470 Scrip Code: 29221

Dear Sir/Madam,

SUB: Outcome of Board Meeting

With reference to the above subject and further to our letter dated July 03, 2017, this is to inform you that the Board of Directors of the Company at their meeting held on Wednesday, July 12, 2017 has approved the Un-Audited Financial Results of the Company for the quarter ended June 30 2017.

In this regard, the Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2017 is enclosed herewith. Further, pursuant to Regulation 33 of the Listing Regulations, the Limited Review Report on the Financial Results for the quarter ended June 30, 2017 enclosed.

Please take the above intimation in your records and kindly acknowledge receipts.

Thanking You,

Yours faithfully,
For Shree Ganesh Bio-Tech (India) Limited


ANIL MISTRY

DIN: 00059558
Director

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:-L70101WB1982PLC121196

Regd. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA WB 700020 IN
Email:-shreeganeshbiotechindia@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2017

(Rs. In lacs)				
Sl no.	Particulars	Quarter Ended 30 June 2017	Quarter Ended 30 June 2016	Year Ended 31 Mar 2017
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME FROM OPERATIONS			
(a)	Net Sales/Income from Operations(Net of Excise Duty)	481.50	48.14	853.67
(b)	Other Operating Income	-	-	-
	Total Income from Operations (Net)	481.50	48.14	853.67
2	EXPENSES			
(a)	Cost of material consumed	-	-	-
(b)	Purchase of stock in trade	198.90	14.06	402.14
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	(4.53)	-
(d)	Employee benefit expense	1.05	2.64	9.81
(e)	Depreciation and amortization expense	-	-	-
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	7.19	5.30	65.68
	Total Expenses	207.14	17.47	477.63
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	274.36	30.67	376.04
4	Other Income	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	274.36	30.67	376.04
6	Finance Costs	-	1.51	2.72
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	274.36	29.16	373.32
8	Exceptional Items	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	274.36	29.16	373.32
10	Tax Expense	-	-	-
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	274.36	29.16	373.32
12	Extraordinary items (net of tax)	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	274.36	29.16	373.32
14	Paid-up equity share capital (Face Value of Rs. 10/- each)	183.12	183.12	183.12
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	667.80
16.i	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised):			
	(a) Basic	14.98	1.59	20.39
	(b) Diluted	14.98	1.59	20.39
16.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised):			
	(a) Basic	14.98	1.59	20.39
	(b) Diluted	14.98	1.59	20.39

Notes:

1

The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 12, 2017. The Statutory Auditors have carried out a limited review of the above financial result.

2 Company has only one segment and hence no separate segment result has been given.

3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.

4 No tax provision have been made as the company is in agricultural business.

5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Kolkata.

Date : 12th July, 2017





Limited Review Report

Review Report To
The Board of Directors of
SHREE GANESH BIO TECH INDIA LIMITED

We have reviewed the accompanying statement of unaudited financial results of **SHREE GANESH BIO TECH INDIA LIMITED** ("The Company") for the quarter ended June 30, 2017 submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: VADODARA
Date: 12.07.2017



For Bipin & Co.
Chartered Accountants
FRNo.: 101509W


(CA Amit Shah)
Partner
M. No.: 126337